CTLA4 and melanoma: It has been reported that SB-3CT, an MMP2/9 inhibitor, could improve the efficacy of anti-PD-1 and anti-CTLA-4 treatment in mouse models with melanoma and lung cancer via regulating PD-L1 expression [214].